Zheng J Cui, 686007 Old Orchard Rd, Kernersville, NC 27284

2007011, May 17, 2007

Oct 25, 2006

11/586227

Zheng Cui - Winston Salem NC, US
Mark Willingham - Summerville SC, US

A01K 67/027
C12N 5/06

800018000, 435354000

We have established and studied a colony of mice with a unique trait of host resistance to both ascites and solid cancers induced by transplantable cells. One dramatic manifestation of this trait is age-dependent spontaneous regression of advanced cancers. This powerful resistance segregates as a single-locus dominant trait, is independent of tumor burden and is effective against cell lines from multiple types of cancer. During spontaneous regression or immediately following exposure, cancer cells provoke a massive infiltration of host leukocytes which form aggregates and rosettes with tumor cells. The cytolytic destruction of cancer cells by innate leukocytes is rapid and specific without apparent damage to normal cells. The mice are healthy, cancer-free and have a normal life span. These observations suggest a previously unrecognized mechanism of immune surveillance that may have potential for therapy or prevention of cancer.

2008008, Apr 17, 2008

Oct 11, 2007

11/870768

Zheng Cui - Winston-Salem NC, US
Mark Willingham - Winston-Salem NC, US

A61K 35/00
A61P 43/00

424093710

A method of treating cancer comprises: (a) providing allogenic or autologous white blood cells from a suitable donor; and then (b) administering the white blood cells to the subject in an amount effective to treat the cancer. Preferably the white blood cells comprise innate immune cells. Preferably the white blood cells comprise less than 10% by number of cytotoxic T lymphocytes. Preferably the white blood cells, or more particularly the innate immune cells, are preselected in vitro to kill cancer cells in vitro (for example, by collecting white blood cells from the patient and determining that the white blood cells kill cancer cells in vitro before and thereby pre-selecting the donor, before collecting a subsequent population of cells from the donor for administration).

2012010, May 3, 2012

Oct 27, 2011

13/282832

Zheng Cui - Winston-Salem NC, US
Mark C. Willingham - Winston-Salem NC, US

A61K 35/14
C40B 30/06
A61P 35/00
C12Q 1/02

424 9371, 435 29, 506 10

A method of treating cancer comprises: (a) providing allogenic or autologous white blood cells from a suitable donor; and then (b) administering the white blood cells to the subject in an amount effective to treat the cancer. Preferably the white blood cells comprise innate immune cells. Preferably the white blood cells comprise less than 10% by number of cytotoxic T lymphocytes. Preferably the white blood cells, or more particularly the innate immune cells, are preselected in vitro to kill cancer cells in vitro (for example, by collecting white blood cells from the patient and determining that the white blood cells kill cancer cells in vitro before and thereby pre-selecting the donor, before collecting a subsequent population of cells from the donor for administration).

2012027, Nov 1, 2012

Jun 28, 2012

13/535824

Zheng Cui - Winston Salem NC, US
Mark c. Willingham - Summerville SC, US

A01K 67/027
A61K 49/00
C12N 5/09

424 92, 800 10, 435354

We have established and studied a colony of mice with a unique trait of host resistance to both ascites and solid cancers induced by transplantable cells. One dramatic manifestation of this trait is age-dependent spontaneous regression of advanced cancers. This powerful resistance segregates as a single-locus dominant trait, is independent of tumor burden and is effective against cell lines from multiple types of cancer. During spontaneous regression or immediately following exposure, cancer cells provoke a massive infiltration of host leukocytes which form aggregates and rosettes with tumor cells. The cytolytic destruction of cancer cells by innate leukocytes is rapid and specific without apparent damage to normal cells. The mice are healthy, cancer-free and have a normal life span. These observations suggest a previously unrecognized mechanism of immune surveillance that may have potential for therapy or prevention of cancer.

2005002, Jan 27, 2005

Apr 19, 2004

10/827654

Zheng Cui - Winston Salem NC, US
Mark Willingham - Summerville SC, US

A01K067/027
C12N005/06

800018000, 435354000

We have established and studied a colony of mice with a unique trait of host resistance to both ascites and solid cancers induced by transplantable cells. One dramatic manifestation of this trait is age-dependent spontaneous regression of advanced cancers. This powerful resistance segregates as a single-locus dominant trait, is independent of tumor burden and is effective against cell lines from multiple types of cancer. During spontaneous regression or immediately following exposure, cancer cells provoke a massive infiltration of host leukocytes which form aggregates and rosettes with tumor cells. The cytolytic destruction of cancer cells by innate leukocytes is rapid and specific without apparent damage to normal cells. The mice are healthy, cancer-free and have a normal life span. These observations suggest a previously unrecognized mechanism of immune surveillance that may have potential for therapy or prevention of cancer.

2021007, Mar 18, 2021

Sep 20, 2019

16/577605

David Xiage Gan - Rockville MD, US
Zheng Cui - Kernersville NC, US

GC Pharmaceutical, INC - Rockville MD

A61K 36/8962

The present invention relates to a pharmaceutical composition. The pharmaceutical composition is the organic phase of raw garlic (all species) or water extraction to provide novel cancer treatments of multiple malignant neoplasms, infectious diseases and Type 2 diabetes. The effective formulation of OPRGE is either liquid or dry powder of OPRGE; the effective routes of administration is intravenous (IV) for infectious diseases and diabetes; the effective routes of administration is intravenous (IV) or intraperitoneal (IP) or intratumoral infusions for malignant neoplasms. The patent application consistent of OPRGE extraction methods, mode of administration of OPRGE and clinical indications.